Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunpeng Fan

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2019
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERDTanya M Laidlaw, Joaquim Mullol, Chunpeng Fan, et al.
Rheumatology and Therapy|May 16, 2019
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic DrugsAlvin F Wells, Janie Parrino, Erin K Mangan, et al.
Arthritis Research & Therapy|September 8, 2016
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trialVibeke Strand, Mark Kosinski, Chieh-I Chen, et al.
Rheumatology (Oxford, England)|May 11, 2018
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomesMark C Genovese, Janet van Adelsberg, Chunpeng Fan, et al.
The Laryngoscope|November 24, 2021
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome ThresholdsChien-Chia Chuang, Isabelle Guillemin, Claus Bachert, et al.
Allergy|November 30, 2018
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposisKarin Jonstam, Brian N Swanson, Leda P Mannent, et al.
Rhinology|November 1, 2019
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNPClaus Bachert, S James Zinreich, Peter W Hellings, et al.
Allergy|July 16, 2019
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposisClaus Bachert, Peter W Hellings, Joaquim Mullol, et al.
The New England Journal of Medicine|April 23, 2025
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in BronchiectasisJames D Chalmers, Pierre-Régis Burgel, Charles L Daley, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 4, 2015
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyMark C Genovese, Roy Fleischmann, Alan J Kivitz, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2019
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERDTanya M Laidlaw, Joaquim Mullol, Chunpeng Fan, et al.
Rheumatology and Therapy|May 16, 2019
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic DrugsAlvin F Wells, Janie Parrino, Erin K Mangan, et al.
Arthritis Research & Therapy|September 8, 2016
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trialVibeke Strand, Mark Kosinski, Chieh-I Chen, et al.
Rheumatology (Oxford, England)|May 11, 2018
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomesMark C Genovese, Janet van Adelsberg, Chunpeng Fan, et al.
The Laryngoscope|November 24, 2021
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome ThresholdsChien-Chia Chuang, Isabelle Guillemin, Claus Bachert, et al.
Allergy|November 30, 2018
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposisKarin Jonstam, Brian N Swanson, Leda P Mannent, et al.
Rhinology|November 1, 2019
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNPClaus Bachert, S James Zinreich, Peter W Hellings, et al.
Allergy|July 16, 2019
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposisClaus Bachert, Peter W Hellings, Joaquim Mullol, et al.
The New England Journal of Medicine|April 23, 2025
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in BronchiectasisJames D Chalmers, Pierre-Régis Burgel, Charles L Daley, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 4, 2015
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyMark C Genovese, Roy Fleischmann, Alan J Kivitz, et al.
Pageof 3